Bexsero logo
UK flag This site is intended for UK health professionals only

A dangerous killer Meningococcal disease can lead to death within 24-48 hours of the first symptoms, leaving a very narrow window for diagnosis and intervention

Life-long impact Among survivors of meningococcal disease,
10%-20% will be left with permanent disabilities

Introducing Bexsero® Bexsero is an innovative vaccine designed to provide broad protection against meningitis B for individuals from 2 months of age and older

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Novartis Vaccines and Diagnostics Limited at